Checked
Class IIIDrug recallOngoing
Nilotinib Capsules recall
Recalled by Cipla USA, Inc. of Warren, NJ · FDA report 03/11/2026
Not an official recall notice and may be delayed. Confirm with the manufacturer or the agency.
- Class
- Class III
- Low risk
- Status
- Ongoing
- Recall started
- 02/18/2026
- Distribution
- Nationwide
Reason for recall
Failed Tablet/Capsule Specifications: Observed OOS results at 6-months long-term stability condition for Description test and Appearance by Visual Inspection test.
Class III: Use of or exposure to the product is not likely to cause adverse health consequences.
Recalled product
- Product
- Nilotinib Capsules, 150 mg per capsule, packaged in cartons, Rx only, Manufactured by: Cipla Ltd., Verna, Goa, India, Manufactured for: Cipla USA, Inc., 10 Independence Boulevard, Suite 300, Warren, NJ 07059, Outer carton: 112 capsules (4 individual packs containing 28 capsules each) NDC 69097-031-74; Inner carton: 28 capsules (4 blisters of 7 capsules) NDC 69097-031-56; Foil blister: NDC 69097-031-17
- Lot and code info
- Lot #: 5GJ0220, 5GJ0221, 5GJ0222, Exp 04/30/2027
- Quantity
- 271 cartons - Ex: 84 outer cartons x 4 inner cartons x 4 blisters x 7 capsules
- Recall number
- D-0381-2026
- Event ID
- 98452
- Initiated by
- Voluntary: Firm initiated
Where it was distributed
U.S.A. Nationwide
- Nationwide
Recall timeline
- 02/18/2026Firm started the recall
- 03/03/2026FDA classified it as Class III
- 03/11/2026Published in the FDA enforcement report
All products in this recall
2 products under event 98452
- D-0381-2026Nilotinib Capsules, 150 mg per capsule, packaged in cartons, Rx only, Manufactured by: Cipla Ltd., Verna, Goa, India, Manufactured for: Cipla USA, Inc., 10... This page
- D-0382-2026Nilotinib Capsules, 200 mg per capsule, packaged in cartons, Rx only, Manufactured for: Cipla USA, Inc., 10 Independence Boulevard, Suite 300, Warren, NJ...
More recalls from Cipla USA
- Class IIDrugOngoing10/14/2026Fosfomycin Tromethamine Granules for Oral Solution, (Equivalent to 3 Grams of Fosfomycin), 1 Single-Dose...Cipla USA, Inc. · Failed Impurities/Degradation Specifications
- Class IIDrugOngoing07/08/2026Cinacalcet Hydrochloride Tablets, 30 mg, 30-count bottle, Rx Only, Manufactured by: Cipla Ltd., MIDC...Cipla USA, Inc. · 3 products · cGMP Deviations: presence of N-nitroso-cinacalcet, above the...
- Class IIDrugOngoing04/22/2026Cinacalcet Hydrochloride Tablets, 30 mg, 30 Tablets per bottle, Rx Only, Manufactured by: Cipla Ltd....Cipla USA, Inc. · 3 products · CGMP Deviations; presence N-Nitroso Cinacalcet above the...
- Class IIDrugOngoing04/15/2026Lanreotide Injection, 120 mg*/0.5 mL, Box contains 1 Pre-filled syringe and 1 safety needle, Single dose...Cipla USA, Inc. · 2 products · Lack of Assurance of Sterility: Due to an FDA observation at the...
- Class IIIDrugOngoing01/28/2026Diclofenac Sodium Topical Gel, 1%, NET WT 100 g (3.53 oz), Manufactured by: DPT Laboratories, Ltd., 307 E...Cipla USA, Inc. · Failed PH Specifications
- Class IIDrugOngoing01/21/2026Lanreotide Injection, 120 mg/0.5 mL, 0.5 mL per pre-filled syringe, For deep subcutaneous injection, Rx...Cipla USA, Inc. · Presence of Particulate Matter.
Frequently asked questions
- Why was Nilotinib Capsules recalled?
- Failed Tablet/Capsule Specifications: Observed OOS results at 6-months long-term stability condition for Description test and Appearance by Visual Inspection test.
- What does Class III mean?
- Class III is FDA's low risk recall category: use of or exposure to the product is not likely to cause adverse health consequences.
- Where was the recalled product sold?
- U.S.A. Nationwide
- Is this recall still active?
- The FDA lists the recall as ongoing. The recall is still in progress.
Source: U.S. Food and Drug Administration, openFDA enforcement report · Last updated 03/11/2026 · Do not rely on openFDA to make decisions regarding medical care